The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies

Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relapsing multiple sclerosis (Lemtrada®). Perhaps due to its histo...

Full description

Bibliographic Details
Main Authors: David Baker, Liaqat Ali, Gauri Saxena, Gareth Pryce, Meleri Jones, Klaus Schmierer, Gavin Giovannoni, Sharmilee Gnanapavan, Kathleen C. Munger, Lawrence Samkoff, Andrew Goodman, Angray S. Kang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Immunology
Subjects:
anti-drug antibodies
CD52
humanized
immunoglobulin
immunogenicity
multiple sclerosis
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00124/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00124/full

Similar Items